Original Article

Prevalence of Atherosclerotic Plaque in Young and Middle-Aged Asymptomatic Individuals: The Bogalusa Heart Study

Objectives: To determine the prevalence of carotid and femoral artery atherosclerotic plaque in a community-based population of asymptomatic African American and white men and women, with an age range of 29 to 51 years, and the potential relations with cardiovascular risk factors. Methods: Between 2007 and 2010, 914 subjects, 58%…

Posted in: atherosclerosis 13 carotid plaque 3 diabetes mellitus 34 Dyslipidemia 4 Hypertension 39

Expired CME Article

Management of Chronic Kidney Disease: What is the Evidence?

Chronic kidney disease (CKD) is a strong risk factor for cardiovascular events and death. Hypertension, dyslipidemia, anemia, vascular calcification, and secondary hyperparathyroidism have all been implicated in the pathogenesis of cardiovascular disease associated with CKD. Numerous trials have been performed assessing the effects of modifying these risk factors on cardiovascular…

Posted in: anemia 11 chronic kidney disease 13 Dyslipidemia 4 Hypertension 39 secondary hyperparathyroidism 3

Expired CME Article

Chronic Kidney Disease: Whom to Screen and How to Treat, Part 1: Definition, Epidemiology, and Laboratory Testing

Chronic kidney disease has become a major public health problem due to its high prevalence, its exorbitant cost, and large reductions in life expectancy and quality of life of affected people. Seventy percent of cases of end-stage renal disease are due to diabetes and hypertension, conditions which are usually managed…

Posted in: anemia 11 chronic kidney disease 13 Dyslipidemia 4 Hypertension 39 screening 33

Case Report

Lipid Lowering Inefficacy of High-dose Statin Therapy Due to Concurrent Use of Phenytoin

HMG-CoA reductase inhibitors (“statins”) are the most commonly prescribed lipid lowering agents. Most of the statins are metabolized by the CYP450 cytochrome system. A number of medications either induce or inhibit this system which leads to changes in the bioavailability of the statins and the potential for either an increase…

Posted in: Dyslipidemia 4 epilepsy 3
SMA Menu